2. Amyotrophic lateral sclerosis Clinical trials / Disease details

Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00600873 (ClinicalTrials.gov)	August 2007	5/1/2008	R(+)PPX High Dose Treatment of ALS	Pharmacokinetics and Nitrative-Oxidative Stress Pharmacodynamics in Amyotrophic Lateral Sclerosis Subjects Taking Daily High-Dose R(+) Pramipexole Dihydrochloride for Six Months	Amyotrophic Lateral Sclerosis	Drug: R(+) pramipexole dihydrochloride monohydrate	Bennett, James P., Jr., M.D., Ph.D.	NULL	Completed	30 Years	80 Years	Both	10	Phase 1/Phase 2	United States
2	NCT00596115 (ClinicalTrials.gov)	October 2005	5/1/2008	Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day	Open Label Extension for Treating ALS With R(+) Pramipexole at 60 Milligrams Per Day	Amyotrophic Lateral Sclerosis	Drug: R(+) pramipexole dihydrochloride monohydrate	Bennett, James P., Jr., M.D., Ph.D.	University of Pittsburgh;University of Nebraska	Temporarily not available	30 Years	80 Years	Both		N/A	NULL
3	NCT00140218 (ClinicalTrials.gov)	August 2005	30/8/2005	R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis	Futility Study of R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: R(+) pramipexole dihydrochloride monohydrate	Bennett, James P., Jr., M.D., Ph.D.	University of Pittsburgh	Completed	21 Years	85 Years	Both	30	Phase 1/Phase 2	United States